Novel molecular targets for the therapy of urothelial carcinoma

Bagi Jana, Matthew D. Galsky, Noah M. Hahn, Matthew I. Milowsky, Guru Sonpavde

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

    Original languageEnglish (US)
    Pages (from-to)499-513
    Number of pages15
    JournalExpert Opinion on Therapeutic Targets
    Volume16
    Issue number5
    DOIs
    StatePublished - May 2012

    Fingerprint

    Clinical Trials
    Carcinoma
    Molecular biology
    Biomarkers
    Platinum
    Cisplatin
    Expert Testimony
    Therapeutics
    Molecular Biology
    Carcinogenesis
    Survival
    Neoplasms

    Keywords

    • Novel molecular targets
    • Targeted therapy
    • Transitional cell carcinoma
    • Urothelial carcinoma

    ASJC Scopus subject areas

    • Drug Discovery
    • Pharmacology
    • Clinical Biochemistry
    • Molecular Medicine

    Cite this

    Jana, B., Galsky, M. D., Hahn, N. M., Milowsky, M. I., & Sonpavde, G. (2012). Novel molecular targets for the therapy of urothelial carcinoma. Expert Opinion on Therapeutic Targets, 16(5), 499-513. https://doi.org/10.1517/14728222.2012.677441

    Novel molecular targets for the therapy of urothelial carcinoma. / Jana, Bagi; Galsky, Matthew D.; Hahn, Noah M.; Milowsky, Matthew I.; Sonpavde, Guru.

    In: Expert Opinion on Therapeutic Targets, Vol. 16, No. 5, 05.2012, p. 499-513.

    Research output: Contribution to journalArticle

    Jana, B, Galsky, MD, Hahn, NM, Milowsky, MI & Sonpavde, G 2012, 'Novel molecular targets for the therapy of urothelial carcinoma', Expert Opinion on Therapeutic Targets, vol. 16, no. 5, pp. 499-513. https://doi.org/10.1517/14728222.2012.677441
    Jana, Bagi ; Galsky, Matthew D. ; Hahn, Noah M. ; Milowsky, Matthew I. ; Sonpavde, Guru. / Novel molecular targets for the therapy of urothelial carcinoma. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. 5. pp. 499-513.
    @article{0f591697b4f84ef194b7ad9c718b920e,
    title = "Novel molecular targets for the therapy of urothelial carcinoma",
    abstract = "Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50{\%} of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.",
    keywords = "Novel molecular targets, Targeted therapy, Transitional cell carcinoma, Urothelial carcinoma",
    author = "Bagi Jana and Galsky, {Matthew D.} and Hahn, {Noah M.} and Milowsky, {Matthew I.} and Guru Sonpavde",
    year = "2012",
    month = "5",
    doi = "10.1517/14728222.2012.677441",
    language = "English (US)",
    volume = "16",
    pages = "499--513",
    journal = "Expert Opinion on Therapeutic Targets",
    issn = "1472-8222",
    publisher = "Informa Healthcare",
    number = "5",

    }

    TY - JOUR

    T1 - Novel molecular targets for the therapy of urothelial carcinoma

    AU - Jana, Bagi

    AU - Galsky, Matthew D.

    AU - Hahn, Noah M.

    AU - Milowsky, Matthew I.

    AU - Sonpavde, Guru

    PY - 2012/5

    Y1 - 2012/5

    N2 - Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

    AB - Introduction: First-line platinum-based combinations are active in locally advanced and metastatic urothelial carcinoma; however, long-term outcomes including disease-specific and overall survival remain suboptimal. In addition, approximately 40 50% of patients with advanced urothelial carcinoma have coexisting medical issues that preclude the use of cisplatin-based therapy. Improvements in our understanding of the molecular mechanisms of urothelial tumorigenesis have led to first-generation clinical trials evaluating novel agents targeting molecular pathways. These are particularly relevant in regard to subpopulations. Novel trial designs warrant consideration to accelerate accrual. Areas covered: In this review, novel molecular targets for the therapy of urothelial carcinoma, as well as recently completed and ongoing clinical trials utilizing novel targeted agents, are discussed. A Medline search with key words, abstracts reported at national conferences on urothelial carcinoma and NCI clinical trial identifiers was used for this review. Expert opinion: Improved understanding of molecular biology has identified a number of new molecular targets, but there is a seeming absence of one dominant molecular driver for urothelial cancer. An adaptive and biomarker-derived strategy may be warranted. Clinical trials utilizing targeted agents are ongoing and results are awaited.

    KW - Novel molecular targets

    KW - Targeted therapy

    KW - Transitional cell carcinoma

    KW - Urothelial carcinoma

    UR - http://www.scopus.com/inward/record.url?scp=84860254010&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84860254010&partnerID=8YFLogxK

    U2 - 10.1517/14728222.2012.677441

    DO - 10.1517/14728222.2012.677441

    M3 - Article

    VL - 16

    SP - 499

    EP - 513

    JO - Expert Opinion on Therapeutic Targets

    JF - Expert Opinion on Therapeutic Targets

    SN - 1472-8222

    IS - 5

    ER -